Results per Page:
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger”
Surprising findings about blood cell mutations bode well for transplant recipients
Fred Hutch researchers compared blood samples from 16 recipient-donor pairs, some more than 45 years after transplant